-
公开(公告)号：US20100261683A1
公开(公告)日：2010-10-14
申请号：US12631373
申请日：2009-12-04
申请人： Ashutosh S. Jogalekar , James P. Snyder , Dennis C. Liotta , Anthony G.M. Barrett , RCDS Coombes , Simak Ali , Aleksandra Siwicka , Jan Brackow , Bodo Scheiper
发明人： Ashutosh S. Jogalekar , James P. Snyder , Dennis C. Liotta , Anthony G.M. Barrett , RCDS Coombes , Simak Ali , Aleksandra Siwicka , Jan Brackow , Bodo Scheiper
IPC分类号： A61K31/635 , C07D487/04 , A61K31/519 , A61P35/00 , C12N9/12
CPC分类号： A61K31/519 , C07D487/04
摘要： This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.
摘要翻译： 本发明提供一类可用于特异性抑制细胞周期蛋白依赖性激酶的化合物。 这类化合物可用于治疗由细胞周期蛋白依赖性激酶（包括癌症，病毒感染（例如HIV））神经变性疾病（例如阿尔茨海默病）和心血管疾病（例如动脉粥样硬化）的不适当活动引起的疾病。 此外，该类的某些成员特别可用于抑制细胞周期蛋白依赖性激酶7，并且特别可用于治疗乳腺癌。
-
公开(公告)号：US08114884B2
公开(公告)日：2012-02-14
申请号：US11328900
申请日：2006-01-09
IPC分类号： A01N43/54 , A01N43/40 , A61K31/505 , A61K31/44 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00
CPC分类号： C07D239/42 , A61K31/4402 , A61K31/444 , A61K31/505 , A61K31/506 , C07C51/412
摘要： The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.
摘要翻译： 本发明提供化合物，药物组合物和使用作为趋化因子CXCR4受体的拮抗剂的某些化合物用于治疗CXCR4受体介导的增殖性病症的化合物，药物组合物和方法。 所提供的化合物干扰SDF1与受体的结合。 这些化合物特别可用于通过抑制转移来治疗或降低过度增殖性疾病的严重性。
-
公开(公告)号：US08067424B2
公开(公告)日：2011-11-29
申请号：US12631373
申请日：2009-12-04
申请人： Ashutosh S. Jogalekar , James P. Snyder , Dennis C. Liotta , Anthony G. M. Barrett , Raoul Charles Dalmedo Stuart Coombes , Simak Ali , Aleksandra Siwicka , Jan Brackow , Bodo Scheiper
发明人： Ashutosh S. Jogalekar , James P. Snyder , Dennis C. Liotta , Anthony G. M. Barrett , Raoul Charles Dalmedo Stuart Coombes , Simak Ali , Aleksandra Siwicka , Jan Brackow , Bodo Scheiper
IPC分类号： C07D487/00 , A01N43/90 , C12N9/12
CPC分类号： A61K31/519 , C07D487/04
摘要： This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.
摘要翻译： 本发明提供一类可用于特异性抑制细胞周期蛋白依赖性激酶的化合物。 这类化合物可用于治疗由细胞周期蛋白依赖性激酶（包括癌症，病毒感染（例如HIV））神经变性疾病（例如阿尔茨海默病）和心血管疾病（例如动脉粥样硬化）的不适当活动引起的疾病。 此外，该类的某些成员特别可用于抑制细胞周期蛋白依赖性激酶7，并且特别可用于治疗乳腺癌。
-
公开(公告)号：US08008312B2
公开(公告)日：2011-08-30
申请号：US11329301
申请日：2006-01-09
IPC分类号： A01N43/54 , A61K31/505 , C07D239/02 , C07D401/00 , C07D403/00 , C07D405/00 , C07D487/00
CPC分类号： C07D239/42 , A61K31/4402 , A61K31/444 , A61K31/505 , A61K31/506 , C07C51/412
摘要： The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor, and in particular to inhibit viral entry of certain viruses. Certain compounds in particular can reduce entry of immunodeficiency virus (HIV) into a cell while not reducing the capacity of stem cells to proliferate, and therefore can be useful for long term treatment regimes. The compounds are useful in particular in the treatment or prevention of HIV infections.
摘要翻译： 本发明提供化合物，药物组合物和使用某些化合物作为趋化因子CXCR4受体的拮抗剂的方法，特别是抑制病毒进入某些病毒。 某些化合物特别可以减少免疫缺陷病毒（HIV）进入细胞，而不会降低干细胞增殖的能力，因此可用于长期治疗方案。 该化合物特别用于治疗或预防HIV感染。
-
15.发明申请Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders 有权雷公藤内酯类似物治疗自身免疫性和炎性疾病公开(公告)号：US20090234000A1
公开(公告)日：2009-09-17
申请号：US12474305
申请日：2009-05-29
IPC分类号： A61K31/336 , C07D303/12
CPC分类号： C07D303/04 , C07C37/002 , C07C45/46 , C07C2601/14 , C07D303/14 , C07D303/32 , C07D493/10 , C07C47/565 , C07C39/11 , C07C39/17
摘要： The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.
摘要翻译： 本发明提供用于治疗自身免疫和抗炎症病症的合成方法和组合物，包括单独给药有效量的雷公藤内酯衍生物或与其他抗自身免疫或抗炎化合物组合或替代。
-
公开(公告)号：US07371766B2
公开(公告)日：2008-05-13
申请号：US10690462
申请日：2003-10-21
申请人： James P. Snyder , Matthew C. Davis , Brian Adams , Mamoru Shoji , Dennis C. Liotta , Eva M. Ferstl , Ustun B. Sunay
发明人： James P. Snyder , Matthew C. Davis , Brian Adams , Mamoru Shoji , Dennis C. Liotta , Eva M. Ferstl , Ustun B. Sunay
IPC分类号： C07D401/14 , C07D407/14 , C07D409/14 , A61K31/4427 , A61K31/445 , A61K31/35 , A61K31/38 , A61P35/00
CPC分类号： C07D295/205 , C07C45/292 , C07C45/62 , C07C45/74 , C07C49/233 , C07C49/235 , C07C49/248 , C07C49/255 , C07C49/697 , C07C49/747 , C07C49/753 , C07C225/22 , C07C235/34 , C07C251/40 , C07C275/24 , C07C317/10 , C07C321/20 , C07D209/34 , C07D213/63 , C07D317/50 , C07D451/02
摘要： The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
摘要翻译： 本发明涉及显示抗肿瘤和抗血管生成性质的姜黄素类似物，包括这些化合物的药物制剂和使用这些化合物的方法。
-
公开(公告)号：US06664272B2
公开(公告)日：2003-12-16
申请号：US09729662
申请日：2000-12-04
申请人： James P. Snyder , Matthew C. Davis , Brian Adams , Mamoru Shoji , Dennis C. Liotta , Eva M. Ferstl , Ustun B. Sunay
发明人： James P. Snyder , Matthew C. Davis , Brian Adams , Mamoru Shoji , Dennis C. Liotta , Eva M. Ferstl , Ustun B. Sunay
IPC分类号： C07D21174
CPC分类号： C07D295/205 , C07C45/292 , C07C45/62 , C07C45/74 , C07C49/233 , C07C49/235 , C07C49/248 , C07C49/255 , C07C49/697 , C07C49/747 , C07C49/753 , C07C225/22 , C07C235/34 , C07C251/40 , C07C275/24 , C07C317/10 , C07C321/20 , C07D209/34 , C07D213/63 , C07D317/50 , C07D451/02
摘要： The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
-
18.发明授权公开(公告)号：US06583292B2
公开(公告)日：2003-06-24
申请号：US10068645
申请日：2002-02-06
申请人： Dennis C. Liotta , Hariharan Venkatesan , Laura Captain , Michael V. Voronkov , James P. Snyder , Marcus A. Schestopol
发明人： Dennis C. Liotta , Hariharan Venkatesan , Laura Captain , Michael V. Voronkov , James P. Snyder , Marcus A. Schestopol
IPC分类号： C07D26308
CPC分类号： C07D263/16 , C07C35/37 , C07C229/34 , C07D263/26 , C07D277/14 , C07D305/14 , C07D413/12
摘要： Described herein is a method for preparing an ester by (a) admixing a compound having the formula I: with a base to form an intermediate, and (b) admixing the intermediate produced in step (a) with a compound composed of an alcohol, an alkoxide, or a combination thereof, wherein steps (a) and (b) are performed in situ.
摘要翻译： 本文描述的是通过（a）将具有式I化合物与碱混合以形成中间体的方法，和（b）将步骤（a）中制备的中间体与由醇组成的化合物混合， 醇盐或其组合，其中步骤（a）和（b）原位进行。
-
公开(公告)号：US20140039187A1
公开(公告)日：2014-02-06
申请号：US13371615
申请日：2012-02-13
IPC分类号： C07D239/42
CPC分类号： C07D239/42 , A61K31/4402 , A61K31/444 , A61K31/505 , A61K31/506 , C07C51/412
摘要： The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.
摘要翻译： 本发明提供化合物，药物组合物和使用作为趋化因子CXCR4受体的拮抗剂的某些化合物用于治疗CXCR4受体介导的增殖性病症的化合物，药物组合物和方法。 所提供的化合物干扰SDF1与受体的结合。 这些化合物特别可用于通过抑制转移来治疗或降低过度增殖性疾病的严重性。
-
20.发明授权Triptolide analogs for the treatment of autoimmune and inflammatory disorders 有权雷公藤内酯类似物用于治疗自身免疫性和炎症性疾病公开(公告)号：US08193249B2
公开(公告)日：2012-06-05
申请号：US12474305
申请日：2009-05-29
IPC分类号： C07D303/00 , A61K31/122
CPC分类号： C07D303/04 , C07C37/002 , C07C45/46 , C07C2601/14 , C07D303/14 , C07D303/32 , C07D493/10 , C07C47/565 , C07C39/11 , C07C39/17
摘要： The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.
摘要翻译： 本发明提供用于治疗自身免疫和抗炎症病症的合成方法和组合物，包括单独给药有效量的雷公藤内酯衍生物或与其他抗自身免疫或抗炎化合物组合或替代。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.059 秒)
